Last edition
News about "Eculizumab "
Samsung Bioepis Partners with Sandoz for Next-Gen Biosimilar Candidates
Samsung Bioepis has partnered with Sandoz to develop and commercialise up to five biosimilar candidates, including SB36 (vedolizumab), across global markets, excluding select Asian regions, strengthening its pipeline in immunology and oncology.
Eculizumab | 19/03/2026 | By News Bureau
Samsung Bioepis Launches BYOOVIZ Biosimilar in Europe
Samsung Bioepis has completed the transfer of BYOOVIZ commercial rights from Biogen, making it the company’s fourth biosimilar directly marketed in Europe, with a pre-filled syringe launch planned for Q2 2026.
Eculizumab | 03/01/2026 | By News Bureau | 121
AstraZeneca Rolls Out Anti-Complement Therapy for aHUS and PNH
AstraZeneca India launches Eculizumab (300 mg, 10 mg/ml), the first approved anti-complement therapy in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), following CDSCO approval in January 2025 for import, sale and distribution.
Eculizumab | 09/09/2025 | By Dineshwori | 166
AstraZeneca Gains CDSCO Nod for Import of Eculizumab in India
Eculizumab is a monoclonal antibody used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement-mediated thrombotic microangiopathy.
Eculizumab | 18/01/2025 | By Aishwarya | 345
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy